And from MSB's CEO
Transcript from Teva's 4Q11
Hi Folks,
I hope you heard the transcript of Teva's CEO 4Q11 report. Below is an extract of his speech which relates to Mesoblast's Revascor product:
"As I said earlier, our acquisition of Cephalon is enabling us to continue the process of establishing an important branded pharmaceutical business with a robust pipeline. We are especially enthusiastic about Treanda , the sNDA
for which was filed in the fourth quarter; REVASCOR for the treatment of congestive heart failure, which is scheduled to begin Phase 3 trials in Q2; and our programs for TB, hydrocodone, and NUVIGIL for the treatment
of bipolar disorder, which are on track for filing this year assuming the successful outcome of their studies".
The above comments of the Teva CEO unambiguously state Teva's intentions with regard to Revascor.
Regards,
Silviu
And from MSB's CEOTranscript from Teva's 4Q11 Hi Folks, I hope...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |